Breathe Well Live Well
Condition: Asthma
Interventions: Drug: Beclomethasone dipropionate; Drug: Placebo; Drug: albuterol/salbutamol 90 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting – verified January 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Beclomethasone dipropionate; Drug: Placebo; Drug: Albuterol/salbutamol
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting – verified January 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Indacaterol 27.5 mcg; Drug: Indacaterol 37.5; Drug: Indacaterol 55 mcg; Drug: Indacaterol 75 mcg; Drug: Indacaterol 150 mcg; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting – verified October 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Mild to Moderate Persistent Asthma
Intervention: Dietary Supplement: Activation Energy Serum
Sponsors: California Allergy and Asthma Medical Group, Inc.; California Allergy and Asthma Medical Group, Inc.
Not yet recruiting – verified September 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Intervention: Drug: Qvar® (beclometasone dipropionate HFA)
Sponsors: University of Dundee; University of Dundee; Teva Pharmaceuticals USA
Not yet recruiting – verified July 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
For Persistent Asthma, Surveyed Pulmonologists Indicate That a Reduced Rate …
PR Newswire (press release) The DecisionBase report entitled Asthma: Where do Pulmonologists and Payers Signal the Greatest Need—and Greatest Opportunity for Differentiation—for Novel Therapies for Persistent Disease? finds that surveyed U.S. and European pulmonologists and … |
View full post on asthma – Google News
Condition: Persistent Asthma
Interventions: Drug: Formoterol; Drug: Fluticasone propionate 100 mcg; Drug: Fluticasone propionate 250 mcg; Drug: Fluticasone propionate 500 mcg; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting – verified April 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Placebo; Drug: JNJ-38518168
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting – verified March 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
BioLineRx's EDP-14, for Treatment of Severe and Persistent Asthma, to Enter …
PharmaLive (press release) (subscription) BL-9010, a novel bi-specific antibody treatment for severe and persistent asthma, targets and links together two immunological modulators – IgE and CD300a. Allergen-bound IgE activates cells involved in allergic responses, such as mast cells, while … |
View full post on asthma – Google News
|
BioLineRx's EDP-14, for Treatment of Severe and Persistent Asthma, to Enter …
MarketWatch (press release) BL-9010, a novel bi-specific antibody treatment for severe and persistent asthma, targets and links together two immunological modulators – IgE and CD300a. Allergen-bound IgE activates cells involved in allergic responses, such as mast cells, while … BIOLINERX LTD. : BioLineRx's EDP-14, for Treatment of Severe and Persistent … |
View full post on asthma – Google News